XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Reconciliation of Segment Loss Before Income Taxes and Total Consolidated Loss Before Income Taxes

The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended June 30, 2025 and 2024 (in thousands):

			Therapeutics Segment
			Three Months Ended June 30,												Six Months Ended June 30,
			2025						2024						2025						2024
Expenses
External research and development expenses - TV programs, including cost sharing			$	37,594					$	30,247					$	84,052					$	65,931
External research and development expenses - small molecule programs, including cost sharing			2,787						12,596						11,641						25,717
Other research and development expenses			22,060						14,504						42,706						30,386
Personnel related research and development expenses			40,255						34,052						80,524						76,381
Total research and development expenses			102,696						91,399						218,923						198,415
Personnel related general and administrative expenses			20,115						17,105						38,853						36,190
Other general and administrative expenses			12,152						8,089						22,767						14,240
Total general and administrative expenses			32,267						25,194						61,620						50,430
Segment operating expenses			134,963						116,593						280,543						248,845
Segment gain from divestiture of small molecule programs			—						—						—						14,537
Segment loss from operations			(134,963)						(116,593)						(280,543)						(234,308)
Segment interest and other income, net			10,844						17,567						23,454						33,480
Segment loss before income taxes			$	(124,119)					$	(99,026)					$	(257,089)					$	(200,828)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration